Corrigendum to: Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials

Benzer Materyaller

• Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials
  Yazar:: Golan, Yoav, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Bezlotoxumab (BEZ) for Prevention of Clostridium Difficile Infection (CDI) Recurrence (rCDI): Outcomes in Patients with Substantial Renal Impairment (SRI)
  Yazar:: Golan, Yoav, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent Clostridium difficile Infection
  Yazar:: Yee, Ka Lai, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection
  Yazar:: Prabhu, Vimalanand S, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Genetic Association Reveals Protection against Recurrence of Clostridium difficile Infection with Bezlotoxumab Treatment
  Yazar:: Shen, Judong, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)